Cyclophosphamide Treatment Options in Cincinnati, OH

A collection of 207 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the Cincinnati, OH. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

NCT05382338

Recruiting

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effective at treating the cancer, there are still concerns about the side effects of such treatment. Side effects or unintended health conditions that arise due to treatment include learning difficulties, hearing loss or other issues in performing daily activities. Standard therapy for newly diagnosed average-risk or low-risk medulloblastoma includes surgery, radiation therapy, and chemotherapy (including cisplatin). Cisplatin may cause hearing loss as a side effect. In the average-risk medulloblastoma patients, this trial tests whether the addition of sodium thiosulfate (STS) to standard of care chemotherapy and radiation therapy reduces hearing loss. Previous studies with STS have shown that it may help reduce or prevent hearing loss caused by cisplatin. In the low-risk medulloblastoma patients, the study tests whether a less intense therapy (reduced radiation) can provide the same benefits as the more intense therapy. The less intense therapy may cause fewer side effects. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. The overall goals of this study are to see if giving STS along with standard treatment (radiation therapy and chemotherapy) will reduce hearing loss in medulloblastoma patients and to compare the overall outcome of patients with medulloblastoma treated with STS to patients treated without STS on a previous study in order to make sure that survival and recurrence of tumor is not worsened. Read Less

Gender:

ALL

Ages:

Between 4 years and 21 years

Trial Updated:

07/10/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +5 locations

Conditions: Childhood Medulloblastoma

Learn More ›

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677

Completed

This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies,... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/25/2025

Locations: Summa Health System - Akron Campus, Akron, Ohio +97 locations

Summa Health System - Akron Campus, Akron, Ohio

Summa Health System - Barberton Campus, Barberton, Ohio

Cleveland Clinic Cancer Center Beachwood, Beachwood, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Mary Rutan Hospital, Bellefontaine, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio

Aultman Health Foundation, Canton, Ohio

Miami Valley Hospital South, Centerville, Ohio

Geauga Hospital, Chardon, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio

Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio

The Christ Hospital, Cincinnati, Ohio

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio

Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

North Coast Cancer Care-Clyde, Clyde, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Columbus NCI Community Oncology Research Program, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Grandview Hospital, Dayton, Ohio

Good Samaritan Hospital - Dayton, Dayton, Ohio

Miami Valley Hospital, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Dayton NCI Community Oncology Research Program, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Delaware Radiation Oncology, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Hematology Oncology Center Incorporated, Elyria, Ohio

Mercy Cancer Center-Elyria, Elyria, Ohio

Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio

Blanchard Valley Hospital, Findlay, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Wayne Hospital, Greenville, Ohio

Cleveland Clinic Cancer Center Independence, Independence, Ohio

Kettering Medical Center, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

Lancaster Radiation Oncology, Lancaster, Ohio

Saint Rita's Medical Center, Lima, Ohio

Lima Memorial Hospital, Lima, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

Saint Luke's Hospital, Maumee, Ohio

Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Landerbrook Health Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

Fisher-Titus Medical Center, Norwalk, Ohio

Saint Charles Hospital, Oregon, Ohio

Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

North Coast Cancer Care, Sandusky, Ohio

UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio

Springfield Regional Medical Center, Springfield, Ohio

Trinity's Tony Teramana Cancer Center, Steubenville, Ohio

Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio

ProMedica Flower Hospital, Sylvania, Ohio

Mercy Hospital of Tiffin, Tiffin, Ohio

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio

Mercy Health - Saint Vincent Hospital, Toledo, Ohio

University of Toledo, Toledo, Ohio

Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

Upper Valley Medical Center, Troy, Ohio

University Hospitals Sharon Health Center, Wadsworth, Ohio

South Pointe Hospital, Warrensville Heights, Ohio

Fulton County Health Center, Wauseon, Ohio

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio

Saint Ann's Hospital, Westerville, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center, Wilmington, Ohio

Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio

Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio

Greene Memorial Hospital, Xenia, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7

Learn More ›

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

NCT03274492

Active Not Recruiting

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

06/24/2025

Locations: Oncology/Hematology Care Clinical Trials LLC, Cincinnati, Ohio +2 locations

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

NCT03150693

Suspended

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or... Read More

Gender:

ALL

Ages:

Between 18 years and 39 years

Trial Updated:

06/24/2025

Locations: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio +4 locations

Conditions: B Acute Lymphoblastic Leukemia

Learn More ›

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

NCT04803201

Recruiting

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: Miami Valley Hospital South, Centerville, Ohio +14 locations

Conditions: Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified

Learn More ›

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

NCT06500273

Recruiting

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/20/2025

Locations: Oncology Hematology Care - Kenwood, Cincinnati, Ohio +2 locations

Conditions: Large B-cell Lymphoma

Learn More ›

Study of LYL314 in Aggressive Large B-Cell Lymphoma

NCT05826535

Recruiting

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/12/2025

Locations: University of Cincinnati (UC) Physicians Company, LLC, Cincinnati, Ohio

Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma

Learn More ›

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

NCT00392327

Active Not Recruiting

This phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma. Chemotherapy drugs, such as vincristine sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination... Read More

Gender:

ALL

Ages:

Between 3 years and 22 years

Trial Updated:

06/04/2025

Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +7 locations

Conditions: Anaplastic Medulloblastoma, Medulloblastoma

Learn More ›

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT03384654

Completed

The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.

Gender:

ALL

Ages:

Between 1 year and 30 years

Trial Updated:

05/22/2025

Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio +1 locations

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Learn More ›

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT02303821

Completed

The purpose of Phase 1b of this study is to: * Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL). * Determine the maximum tolerated dose (MTD) and to recommend a phase 2 dose of carfilzomib in combination with induction chemotherapy. The purpose of Phase 2 of this study is to compare the rate of complete remission (CR) of carfilzomib in combination with vin... Read More

Gender:

ALL

Ages:

Between 1 month and 21 years

Trial Updated:

05/16/2025

Locations: Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio +2 locations

Conditions: Acute Lymphoblastic Leukemia (ALL)

Learn More ›

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00006721

Active Not Recruiting

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibod... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/12/2025

Locations: McDowell Cancer Center at Akron General Medical Center, Akron, Ohio +34 locations

McDowell Cancer Center at Akron General Medical Center, Akron, Ohio

Mary Rutan Hospital, Bellefontaine, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Good Samaritan Hospital Cancer Treatment Center, Cincinnati, Ohio

Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio

Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Riverside Methodist Hospital Cancer Care, Columbus, Ohio

CCOP - Columbus, Columbus, Ohio

Grant Medical Center Cancer Care, Columbus, Ohio

Mount Carmel Health - West Hospital, Columbus, Ohio

Doctors Hospital at Ohio Health, Columbus, Ohio

Grandview Hospital, Dayton, Ohio

Good Samaritan Hospital, Dayton, Ohio

David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio

Samaritan North Cancer Care Center, Dayton, Ohio

Veterans Affairs Medical Center - Dayton, Dayton, Ohio

CCOP - Dayton, Dayton, Ohio

Grady Memorial Hospital, Delaware, Ohio

Blanchard Valley Medical Associates, Findlay, Ohio

Middletown Regional Hospital, Franklin, Ohio

Community Oncology Group at Cleveland Clinic Cancer Center, Independence, Ohio

Charles F. Kettering Memorial Hospital, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

St. Rita's Medical Center, Lima, Ohio

Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio

Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio

Mercy Medical Center, Springfield, Ohio

Community Hospital of Springfield and Clark County, Springfield, Ohio

UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio

Mount Carmel St. Ann's Cancer Center, Westerville, Ohio

Clinton Memorial Hospital, Wilmington, Ohio

Cleveland Clinic - Wooster, Wooster, Ohio

Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio

Genesis - Good Samaritan Hospital, Zanesville, Ohio

Conditions: Lymphoma

Learn More ›

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

NCT02723994

Active Not Recruiting

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.

Gender:

ALL

Ages:

Between 1 year and 21 years

Trial Updated:

04/30/2025

Locations: Akron Children'S Hospital, Akron, Ohio +6 locations

Conditions: Leukemia

Learn More ›

Browse Cyclophosphamide Treatment Options in Other Ohio Cities

Cyclophosphamide treatment options in Columbus

Cyclophosphamide treatment options in Cleveland